Company / Cash & Equivalents
MIMEDX GROUP, INC. Cash & Equivalents History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$166.1M
FY2025
5-year range
$66.0M / $166.1M
FY2021-FY2025
Trend
+59.1%
vs FY2024
Sector context
#88 of 148
Health Care
What the data says
At $166M, MIMEDX GROUP, INC.'s cash & equivalents ranks #88 of 148 in the Health Care sector. Cash & Equivalents has increased for 3 consecutive years, from $66M in FY2022 to $166M in FY2025.
Based on SEC 10-K filings.
$166M in FY2025 with a 5-year CAGR of +11.6%.
Improved from $82M to $166M over the past 2 years.
Health Care sector context is included.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- +36.1%
- 5-Year CAGR
- +11.6%
- 10-Year CAGR
- -
Sector benchmark
#88 of 148 in Health CareTop 59% of 148This company $166.1M Sector average $1.2B
▼
-86.1% below sector average
Key checks
Key Insights
- MIMEDX GROUP, INC.'s cash & equivalents has grown for 3 consecutive years.
- 5-year CAGR of +11.6%, indicating consistent growth.
- In FY2025, cash & equivalents increased 59.1% year-over-year.
- Ranks #88 out of 148 companies in the Health Care sector.
Company context
Key Data Points
- Altman Z-Score 3.50 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $166.1M | +59.1% |
| FY2024 | $104.4M | +27.3% |
| FY2023 | $82.0M | +24.3% |
| FY2022 | $66.0M | -24.3% |
| FY2021 | $87.1M | -9.1% |
| FY2020 | $95.8M | +38.7% |
| FY2019 | $69.1M | +53.1% |
| FY2018 | $45.1M | +64.2% |
| FY2017 | $27.5M | -9.4% |
| FY2016 | $30.3M | +15.3% |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026